DE60336027D1 - Impfstoffe auf mannoproteinfreier Beta-Glucan-Basis - Google Patents

Impfstoffe auf mannoproteinfreier Beta-Glucan-Basis

Info

Publication number
DE60336027D1
DE60336027D1 DE60336027T DE60336027T DE60336027D1 DE 60336027 D1 DE60336027 D1 DE 60336027D1 DE 60336027 T DE60336027 T DE 60336027T DE 60336027 T DE60336027 T DE 60336027T DE 60336027 D1 DE60336027 D1 DE 60336027D1
Authority
DE
Germany
Prior art keywords
glucan
antibodies
protective
presented
mannoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60336027T
Other languages
English (en)
Inventor
Luciano Polonelli
Antonio Cassone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60336027D1 publication Critical patent/DE60336027D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DE60336027T 2002-05-15 2003-05-15 Impfstoffe auf mannoproteinfreier Beta-Glucan-Basis Expired - Lifetime DE60336027D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0211118.5A GB0211118D0 (en) 2002-05-15 2002-05-15 Vaccines

Publications (1)

Publication Number Publication Date
DE60336027D1 true DE60336027D1 (de) 2011-03-24

Family

ID=9936711

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60336027T Expired - Lifetime DE60336027D1 (de) 2002-05-15 2003-05-15 Impfstoffe auf mannoproteinfreier Beta-Glucan-Basis
DE60320979T Expired - Lifetime DE60320979D1 (de) 2002-05-15 2003-05-15 Impfstoffe gegen Pilzen aus Beta-Glucan

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60320979T Expired - Lifetime DE60320979D1 (de) 2002-05-15 2003-05-15 Impfstoffe gegen Pilzen aus Beta-Glucan

Country Status (15)

Country Link
US (4) US20050208079A1 (de)
EP (2) EP1506009B1 (de)
JP (3) JP5110767B2 (de)
AT (2) ATE497781T1 (de)
AU (1) AU2003241104A1 (de)
CA (2) CA2485847C (de)
CY (1) CY1108234T1 (de)
DE (2) DE60336027D1 (de)
DK (1) DK1506009T3 (de)
ES (1) ES2306871T3 (de)
GB (1) GB0211118D0 (de)
HK (2) HK1069125A1 (de)
PT (1) PT1506009E (de)
SI (1) SI1506009T1 (de)
WO (1) WO2003097091A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US8071552B2 (en) * 2004-04-05 2011-12-06 Universite Bordeaux 2 Peptides and peptidomimetics binding to CD23
GB0420466D0 (en) * 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
EP1896062B1 (de) 2005-06-27 2010-03-31 GlaxoSmithKline Biologicals S.A. Immunogene zusammensetzung
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP1984004A4 (de) * 2006-01-17 2010-03-03 Sloan Kettering Inst Cancer Die therapie verstärkendes glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
US20070253985A1 (en) * 2006-04-26 2007-11-01 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
AU2013203785B2 (en) * 2006-11-06 2016-11-17 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
EP2066294B9 (de) * 2006-11-06 2013-04-10 Whitehead Institute Immunmodulierende zusammensetzungen und verfahren zu ihrer verwendung
JP4687644B2 (ja) 2006-12-22 2011-05-25 富士ゼロックス株式会社 画像処理装置、画像読取装置及び画像形成装置
US9439954B2 (en) * 2007-11-26 2016-09-13 Glaxosmithkline Biologicals Sa Conjugated beta-1,3-linked glucans
JP5588874B2 (ja) * 2007-11-26 2014-09-10 ノバルティス アーゲー アジュバント添加されたグルカン
US8617823B2 (en) * 2008-04-29 2013-12-31 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
AU2009294318B2 (en) 2008-09-18 2014-04-24 Novartis Ag Vaccine adjuvant combinations
NL1036661C2 (en) 2009-03-04 2010-09-07 Serrix B V Anti-fungal compounds & compositions.
AU2010222267A1 (en) * 2009-03-10 2011-10-27 Palmed Teva Ltd Novel Coprinus comatus and Tremella mesenterica mushroom strains, products and extracts thereof and compositions comprising them
EP2470205A1 (de) 2009-08-27 2012-07-04 Novartis AG Hilfsstoff mit aluminium, oligonukleotid und polykation
JP5988492B2 (ja) 2009-09-02 2016-09-07 ノバルティス アーゲー Ｔｌｒ活性モジュレーターを含む免疫原性組成物
US20110189183A1 (en) 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
NZ623714A (en) * 2010-05-14 2015-10-30 Alltech Inc Yeast cell wall components and detection thereof
EP2719395A1 (de) 2010-09-01 2014-04-16 Novartis AG Adsorption von Immunpotentiatoren auf unlöslichen Metallsalzen
ES2630029T3 (es) 2010-12-14 2017-08-17 Glaxosmithkline Biologicals Sa Análisis de citometría de flujo de materiales adsorbidos en sales metálicas
CA2828844C (en) 2011-03-02 2020-07-14 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
WO2013009564A1 (en) 2011-07-08 2013-01-17 Novartis Ag Tyrosine ligation process
EP2776069A1 (de) 2011-11-07 2014-09-17 Novartis AG Trägermolekül mit einem spr0096- und einem spr2021-antigen
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
LT2822947T (lt) 2012-03-07 2016-10-10 Glaxosmithkline Biologicals Sa Tlr7 agonisto arginino druskos
WO2013132041A2 (en) 2012-03-08 2013-09-12 Novartis Ag Adjuvanted formulations of booster vaccines
RU2629334C2 (ru) * 2012-04-30 2017-08-28 Байотера, Инк. КОМПОЗИЦИИ И СПОСОБЫ ДЛЯ β-ГЛЮКАНОВОЙ ИММУНОТЕРАПИИ
JP6411378B2 (ja) 2013-02-01 2018-10-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｔｏｌｌ様受容体アゴニストを含む免疫学的組成物の皮内送達
CN103083663B (zh) * 2013-02-04 2014-12-10 江苏省农业科学院 一种免疫增强剂、灭活疫苗及其制备方法
PL2968427T3 (pl) 2013-03-12 2023-02-27 Wellstat Vaccines, Llc Koniugat do indukowania przeciwciał ukierunkowanych na polisacharydy ściany komórkowej grzybów
CN105593238B (zh) 2013-07-11 2020-09-08 诺华股份有限公司 使用微生物转谷氨酰胺酶进行赖氨酸特异性化学酶法蛋白质修饰
CA2932192C (en) * 2013-12-05 2020-10-06 Biothera, Inc. .beta.-glucan assay methods
CN104771498A (zh) * 2015-03-13 2015-07-15 臧海阳 一种治疗热毒蕴结型痄腮的中药组合物
US11815435B2 (en) 2017-02-24 2023-11-14 Hibercell, Inc. Beta glucan immunopharmacodynamics
US20200353004A1 (en) * 2018-01-19 2020-11-12 Miltenyi Biotec B.V. & Co. KG Regulatory T Cell Expressing a Chimeric Antigen Receptor
US11701417B2 (en) * 2019-03-27 2023-07-18 West Virginia University Vaccine formulation to protect against pertussis
WO2023002252A1 (en) 2021-07-21 2023-01-26 Bioatlantis Limited Composition comprising beta-glucans and alpha-fucans for improving gut health and animal performance and methods of making the same
WO2023161526A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
WO2023161527A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE466289B (sv) * 1984-09-19 1992-01-27 James Hoffman Makrofagstimulerande komposition jaemte foerfarande foer dess framstaellning
JPS6383012A (ja) * 1986-09-26 1988-04-13 Nonogawa Shoji:Kk 化粧料
EP0490995A1 (de) * 1989-09-08 1992-06-24 Alpha Beta Technology Verfahren zur herstellung von wasserlöslichen glukanen
EP0471954A3 (en) * 1990-08-13 1993-03-03 American Cyanamid Company Immunogenic conjugates of nontoxic oligosaccharide derived from bordetella pertussis lipooligosaccharide
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
ATE280235T1 (de) * 1993-03-05 2004-11-15 Wyeth Corp Plasmid zur herstellung von crm-protein und diphtherie-toxin
CN1094288A (zh) * 1993-04-23 1994-11-02 福建省微生物研究所 利用红色诺卡氏菌制造细胞壁骨架粉末的方法
NO300692B1 (no) 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan
US6309642B1 (en) * 1997-04-28 2001-10-30 The Research And Development Institute, Inc. Peptides which mimic candida carbohydrate epitopes and their use in a vaccine
AUPN166195A0 (en) * 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
JPH09309842A (ja) * 1996-05-20 1997-12-02 Kureha Chem Ind Co Ltd 新規な生理活性物質、その製造方法及び医薬組成物
AU760669B2 (en) * 1998-04-28 2003-05-22 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
JP4230635B2 (ja) 2000-02-29 2009-02-25 富士フイルム株式会社 デジタルカメラ

Also Published As

Publication number Publication date
CA2830619A1 (en) 2003-11-27
HK1069125A1 (en) 2005-05-13
JP2010131017A (ja) 2010-06-17
JP2012224636A (ja) 2012-11-15
EP1506009B1 (de) 2008-05-14
AU2003241104A1 (en) 2003-12-02
US20110059120A1 (en) 2011-03-10
WO2003097091A3 (en) 2004-03-04
JP2005535298A (ja) 2005-11-24
PT1506009E (pt) 2008-08-14
US20070141088A1 (en) 2007-06-21
DK1506009T3 (da) 2008-09-01
JP5110767B2 (ja) 2012-12-26
US7824688B2 (en) 2010-11-02
JP5684758B2 (ja) 2015-03-18
DE60320979D1 (de) 2008-06-26
WO2003097091A2 (en) 2003-11-27
CA2485847C (en) 2013-12-31
ES2306871T3 (es) 2008-11-16
US8398990B2 (en) 2013-03-19
CA2485847A1 (en) 2003-11-27
GB0211118D0 (en) 2002-06-26
US8679506B2 (en) 2014-03-25
HK1114335A1 (en) 2008-10-31
ATE395080T1 (de) 2008-05-15
EP1506009A2 (de) 2005-02-16
EP1891970A1 (de) 2008-02-27
SI1506009T1 (sl) 2008-10-31
EP1891970B1 (de) 2011-02-09
US20130171187A1 (en) 2013-07-04
CY1108234T1 (el) 2014-02-12
ATE497781T1 (de) 2011-02-15
US20050208079A1 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
DE60336027D1 (de) Impfstoffe auf mannoproteinfreier Beta-Glucan-Basis
WO2000045792A8 (en) Hydrogel particle formulations
EP2266607A3 (de) Immunokonjugate für Krebsbehandlung
PL377146A1 (pl) Cytokiny ochronne dla tkanek do ochrony, odnowy i wzmacniania reaktywnych komórek, tkanek i narządów
MX368377B (es) Combinacion de brimonidina y timolol para uso oftalmico, topico.
CA2378892A1 (en) Preserved pharmaceutical formulations
WO2004108093A3 (en) Antiseptic compositions, methods and systems
WO2003045306A3 (en) Phenoxy amine compounds and compositions for delivering active agents
WO2005000241A3 (en) Compositons and methods for topical administration
DE60036915D1 (de) Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
PT1121127E (pt) Composicoes farmaceuticas orais contendo buprenorfina
ATE270115T1 (de) Behandlung einer intrazelluläre infektion
EA200501828A1 (ru) Тканепротекторные цитокины с увеличенным терапевтическим окном для защиты, восстановления и стимулирования реагирующих клеток, тканей и органов
WO2003082926A3 (en) Antimicrobial polymer conjugates
WO2000074649A3 (en) Ophthalmic histamine compositions and uses thereof
EP4295917A3 (de) Bioorthogonale trans-cycloocten-wirkstoffe und verwendungen in krebs und immuntherapie
WO2003099241A3 (en) Sunscreen compositions and methods of use thereof
WO2004006851A3 (en) Mycoplasma gallisepticum formulation
WO2002055022A3 (en) Active metabolite of antifungal compound
WO2003000174A3 (en) Compositions and methods for intracellular delivery
NZ584942A (en) Injectable meclizine formulations and methods comprising a molar excess of a modified cyclodextrin
ATE238050T1 (de) 4-cyano-4-deformylsordarizin-derivate
WO2004052331A3 (fr) Utilisation d'un extrait de miellat de coton comme ingredient acitif
EP0943339A3 (de) Verfahren zur Verhinderung der Abstossungsreaktion allogener Transplantate
HK1064955A1 (en) Composition comprising demethylcantharidin in combination with platinum-containing anticancer agentsand use thereof